TrialMedicina (Kaunas, Lithuania)2023

A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy.

Seunghoon Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.